Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
13 trends tracked about this subject — the full history, oldest to newest below.
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.
Vaxcyte stock surges following phase 3 trial results for its pneumococcal vaccine candidate in a lucrative market.
New research suggests that limiting sugar intake during antibiotic treatment may help protect the gut microbiome from amplified damage.
Recent coverage highlights prostate cancer awareness, screenings, and expert research retreats.
Enveda secures $311 million in venture funding to advance nature-derived AI drugs into clinical trials.
Takeda Pharmaceutical's R&D chief Andy Plump is set to retire in June 2027 following a period of significant pipeline reorganization and regulatory success.
A major Novartis shareholder is demanding a board overhaul following a series of costly drug trial setbacks and strategic failures.
Novartis stock experiences a sharp decline following a Phase 3 failure for a dystrophy drug linked to its $12 billion Avidity acquisition.
GSK advances its mRNA flu vaccine candidate to phase 3 trials following successful mid-stage performance data.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.